Table 5.
Relevance of OVA-YOND results within the context of trabectedin plus pegylated liposomal doxorubicin treatment of recurrent platinum-sensitive ovarian cancer
| Studies | n | Age Median (range) |
Prior chemotherapy lines Median (range) |
ECOG PS score 0/1 | Platinum-sensitive patients (PFI ≥ 6 months) | ||
|---|---|---|---|---|---|---|---|
| ORR (%) | Median PFS (months) | Median OS (months) | |||||
| Real-world outcomes | |||||||
| Moriceau et al. (2016)a | 17 | 61 (48–78) | 3 (1–9) | 94.1 | 53.0 | 6.7 | 17.6 |
| Nicoletto et al. (2015) | 34 | 60 (26–79) | 3 (2–10) | NR | 32.4 | 6.1 | 16.3 |
| OVA-YOND study | |||||||
| Runnebaum et al. | 77 | 66 (40–78) | 2.0 (1–6) | 80.5 | 31.2 | 6.3 | 16.4 |
ECOG Eastern Cooperative Oncology Group, NR not reported, ORR overall response rate, OS overall survival, PFI platinum-free interval, PFS progression-free survival, PS performance status
aTen patients (59%) had platinum-resistant disease with a PFI < 6 months